Company: LGN
Filing Date: 2025-08-25
Form Type: S-1/A
Source: 0001193125-25-186788
Chunk: 208

Company: Legence Corp.
Filing Date: 2025-08-25
Form: S-1/A
Chunk 208
---
 shares subject to an award under the 2025 Plan. The Committee will also have the discretion to make certain adjustments to awards in the event of a change in control, such as accelerating
the vesting or exercisability of awards, requiring the surrender of an award, with or without consideration, or making any other adjustment or modification to the award that the Committee determines is appropriate in light of such transaction.

149

Clawback

All awards granted under the 2025 Plan will be subject to clawback, cancellation, recoupment, rescission, payback, reduction, or other similar
action in accordance with any Company clawback or similar policy or any applicable law related to such actions.

Amendment and Termination

Our board of directors or the Committee may amend or terminate the 2025 Plan at any time; however, stockholder approval
will be required for any amendment to the extent necessary to comply with applicable law. Stockholder approval will be required to make amendments that (i) increase the aggregate number of shares that may be issued under the 2025 Plan or
(ii) change the classification of individuals eligible to receive awards under the 2025 Plan. The 2025 Plan will remain in effect for a period of 10 years (unless earlier terminated by our board of directors).

IPO Grants

In connection with this
offering, we expect to grant restricted stock units and stock options under the 2025 Plan to certain employees (collectively, the “IPO Grants”), including our named executive
officers, assuming an initial public offering price of $ per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, with the actual number of restricted stock units and stock
options to be determined at the pricing of this offering. Each stock option granted as of the pricing of this offering will have an exercise price equal to the initial public offering price in this offering. As of the date of this prospectus, the
individual award values for each named executive officer are not yet known. Each IPO Grant to our named executive officers will consist of 50% of restricted stock units and 50% stock options, both of which will vest in three substantially equal
installments on each of the first, second and third anniversaries of the applicable vesting commencement date, subject generally to continued employment through the applicable vesting date.

150

PRINCIPAL AND SELLING STOCKHOLDERS The following table sets forth certain information regarding the beneficial ownership of our